Canada markets open in 3 hours 15 minutes

PureTech Health plc (PRTC)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
21.00+0.49 (+2.39%)
At close: 01:47PM EST
20.62 -0.38 (-1.81%)
Pre-Market: 04:05AM EST

PureTech Health plc

6 Tide Street
Suite 400
Boston, MA 02210
United States
617 482 2333

Full Time Employees111

Key Executives

NameTitlePayExercisedYear Born
Ms. Daphne ZoharFounder, CEO & Executive Director1.01MN/A1971
Dr. Bharatt M. Chowrira J.D., Ph.D.President, Secretary, Chief Business Finance & Operating Officer and Executive Director800.55kN/A1965
Dr. Robert S. Langer Jr., Ph.D.Co-Founder & Non-Executive Director145kN/A1949
Dr. David R. Elmaleh Ph.D.Co-Founder & Senior AdvisorN/AN/A1948
Ms. Allison Mead TalbotHead of Communications & Investor RelationsN/AN/AN/A
Mr. Spencer BallSenior Vice President of Human ResourcesN/AN/AN/A
Dr. Eric Elenko Ph.D.Chief Innovation & Strategy OfficerN/AN/A1973
Ms. Aleksandra Filipovic M.D., Ph.D.Head of OncologyN/AN/AN/A
Ms. Cheryl Murphy Ph.D.Head of Grants Management & StrategyN/AN/AN/A
Ms. Anita Terpstra J.D., Ph.D.Senior VP & Head of Intellectual PropertyN/AN/AN/A
Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


PureTech Health plc, a clinical stage biotherapeutics company, engages in the discovery, development, and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, currently under Phase 3 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, to inhibit the activity of galectin-9 for treating solid tumors and hematological malignancies. It is also developing LYT-300, an oral allopregnanolone, currently completed Phase 1 stage, to treat depression, anxiety, and related indications; and LYT-310, an oral cannabidiol, currently under preclinical stage, to treat epilepsies and other neurological indications. In addition, the company is developing LYT-503/IMB-150, a non-opioid inflammation targeted disease immunomodulation for the potential treatment of interstitial cystitis, or bladder pain syndrome; and Glyph technology platform, a lymphatic-targeting chemistry platform, which leverages the body's natural lipid absorption and transports the process to orally administer drugs via the lymphatic system. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.

Corporate Governance

PureTech Health plc’s ISS Governance QualityScore as of November 1, 2023 is 9. The pillar scores are Audit: 10; Board: 3; Shareholder Rights: 1; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.